All posts by: Michael Zand

About Michael Zand

The Problem With Miracle Cancer Cures – New York Times

Continue reading

2018-04-19 NEWS

New York Times

The Problem With Miracle Cancer Cures
New York Times
A recent analysis estimated that about 15 percent of patients with advanced cancer might benefit from immunotherapy — and it’s all but impossible to determine which patients will be the lucky ones. Just last week, a study of lung cancer patients
Hellman Expands on TMB Testing in Lung CancerOncLive

all 2 news articles »

Continue reading

2018-04-19 NEWS

Regulatory Focus

Recon: Bluebird’s gene therapy eliminates blood transfusions for some beta-thalassemia patients
Regulatory Focus
… AI pharma start-up BenevolentAI now worth $2 billion after $115 million funding boost (CNBC) (TechCrunch) (Reuters) (Business Insider) (Endpoints); Kleiner Perkins’ Beth Seidenberg bumps Tmunity’s cell therapy round to $135M (Endpoints) (Fierce

Continue reading

2018-04-19 NEWS

Endpoints News

Tocagen licenses immunotherapy to ApolloBio for $16M upfront; WuXi AppTec unveils expanded lab testing site in …
Endpoints News
San Diego-based Tocagen $TOCA has inked a licensing deal with ApolloBio, giving an affiliate of the Beijing-based company an exclusive license to develop and commercialize its cancer-selective immunotherapy. Tocagen’s treatment, called Toca 511 & Toca
Tocagen (TOCA) Reports License Agreement with Beijing Apollo …StreetInsider.com

all 7 news articles »

Continue reading

2018-04-19 NEWS

Endpoints News

Tocagen licenses immunotherapy to ApolloBio for $16M upfront; WuXi AppTec unveils expanded lab testing site in …
Endpoints News
San Diego-based Tocagen $TOCA has inked a licensing deal with ApolloBio, giving an affiliate of the Beijing-based company an exclusive license to develop and commercialize its cancer-selective immunotherapy. Tocagen’s treatment, called Toca 511 & Toca
Tocagen (TOCA) Reports License Agreement with Beijing Apollo …StreetInsider.com

all 7 news articles »

Continue reading

2018-04-19 NEWS

euronews

Hungary: Siberian tiger receives stemcell surgery for joint pain
euronews
Hungarian veterinarians operated on Wednesday on the first Siberian tiger to receive a Lipogems stemcell treatment for a hip joint problem. The Lipogems surgery is a stemcell procedure that uses the patient’s own fatty tissues to get regenerative

and more »